<DOC>
	<DOCNO>NCT00187512</DOCNO>
	<brief_summary>SCOPE observational , prospective study HIV-1 infect volunteer design provide specimen bank sample carefully characterize clinical data . SCOPE specimens use examine multiple question involve virologic , immunologic , host factor involve HIV-1 infection , progression , non-progression , response treatment , control HIV-1 virus , evolution drug resistance .</brief_summary>
	<brief_title>SCOPE : Observational Study Consequences Protease Inhibitor Era</brief_title>
	<detailed_description>SCOPE observational , prospective study HIV-1 infect volunteer design provide specimen bank sample carefully characterize clinical data . Samples SCOPE use examine : 1 . Virologic , immunologic , host factor involve natural control HIV-1 infection ( long term non-progression and/or virologic control HIV-1 without antiretroviral therapy ) 2 . Virologic immune correlate associate disease progression 3 . Evolution antiretroviral drug resistance 4 . Factors associated transmission acquisition HIV infection Enrolled subject see San Francisco General Hospital every four month detail interview , saliva collection , blood draw . Baseline visit take approximately one hour , follow visit take approximately 20-40 minute . No personal identifier use specimen bank sample .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>SCOPE currently recruit HIV1 infected subject follow criterion : 1 . Documented HIV viral load less 2000 copies/ml WITHOUT take antiretroviral therapy 2 . Undetectable HIV viral load CD4 Tcells consistently less 350 last 12 month take stable antiretroviral regimen . 3 . Antiretroviral naive plan start antiretroviral regimen CD4 HIV viral load acceptable . 4 . Longterm Non Progressors : HIVpositive least 10 year , antiretroviral therapy past 10 year , viral load acceptable , CD4T cell count always 500 . 1 . Active opportunistic infection systemic treatment opportunistic infection within last 4 month ( oral candidiasis acceptable ) 2 . Active treatment cancer 3 . Active treatment hepatitis C require interferon base therapy 4 . Immunosuppressive therapy take within last 4 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>Antiretroviral Agents</keyword>
	<keyword>Drug Resistance , Multiple</keyword>
	<keyword>Long Term Non Progression</keyword>
	<keyword>Long Term Non Progressor</keyword>
	<keyword>Elite Suppression</keyword>
	<keyword>Elite Suppressor</keyword>
	<keyword>Natural History</keyword>
	<keyword>Observational</keyword>
</DOC>